IVVD
Invivyd Inc
NASDAQ · Biotechnology
$1.59
-0.12 (-7.02%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 59.33M | 178.19M | 160.29M | 142.80M |
| Net Income | -397,200,152 | 4.92M | 3.11M | 2.81M |
| EPS | — | — | — | — |
| Profit Margin | -669.4% | 2.8% | 1.9% | 2.0% |
| Rev Growth | — | +11.2% | +5.5% | +8.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 41.24M | 37.88M | 36.70M |
| Total Equity | — | 228.36M | 219.75M | 214.56M |
| D/E Ratio | — | 0.18 | 0.17 | 0.17 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -410,141,788 | 6.39M | 5.91M | 5.38M |
| Free Cash Flow | — | 2.75M | 2.88M | 2.77M |